Compare · ARGX vs KYMR
ARGX vs KYMR
Side-by-side comparison of argenx SE (ARGX) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and KYMR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 5.6x KYMR ($9.52B).
- KYMR has been more active in the news (42 items in the past 4 weeks vs 3 for ARGX).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Kymera Therapeutics Inc.
- Price
- -
- -
- Market cap
- $53.41B
- $9.52B
- 1M return
- -
- +32.60%
- 1Y return
- -
- +150.41%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 3
- 42
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest KYMR
- Chief Executive Officer Mainolfi Nello exercised 50,000 shares at a strike of $2.08 and sold $5,950,000 worth of shares (50,000 units at $119.00) as part of a pre-agreed trading plan (SEC Form 4)
- Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
- Chief Business Officer Goodman Noah sold $387,329 worth of shares (3,389 units at $114.29) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 47,179 units (SEC Form 4)
- Chief Financial Officer Jacobs Bruce N. exercised 61,378 shares at a strike of $5.33 and sold $8,864,829 worth of shares (77,109 units at $114.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 244,883 units (SEC Form 4)
- Chief Executive Officer Mainolfi Nello sold $9,223,527 worth of shares (80,000 units at $115.29) as part of a pre-agreed trading plan and exercised 80,000 shares at a strike of $2.08 (SEC Form 4)
- Amendment: Director Booth Bruce sold $8,281,905 worth of shares (76,650 units at $108.05) as part of a pre-agreed trading plan (SEC Form 4)
- Director Booth Bruce sold $3,424,800 worth of shares (31,283 units at $109.48) as part of a pre-agreed trading plan (SEC Form 4)
- Director Booth Bruce sold $56,460,136 worth of shares (513,245 units at $110.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Kymera Therapeutics Inc.
- SEC Form 144 filed by Kymera Therapeutics Inc.